These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 32221162)

  • 1. Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH).
    Huang CF; Lai HC; Chen CY; Tseng KC; Kuo HT; Hung CH; Wang JH; Chen JJ; Lee PL; Chien RN; Yang CC; Lo GH; Tai CM; Lin CW; Kao JH; Liu CJ; Liu CH; Yan SL; Bair MJ; Lin CY; Su WW; Chu CH; Chen CJ; Tung SY; Lo CC; Cheng PN; Chiu YC; Wang CC; Cheng JS; Tsai WL; Lin HC; Huang YH; Yeh ML; Huang JF; Dai CY; Chuang WL; Tsai PC; Peng CY; Yu ML
    Am J Gastroenterol; 2020 Aug; 115(8):1226-1235. PubMed ID: 32221162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection.
    Mahale P; Engels EA; Li R; Torres HA; Hwang LY; Brown EL; Kramer JR
    Gut; 2018 Mar; 67(3):553-561. PubMed ID: 28634198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort).
    Hsu WF; Tsai PC; Chen CY; Tseng KC; Lai HC; Kuo HT; Hung CH; Tung SY; Wang JH; Chen JJ; Lee PL; Chien RN; Lin CY; Yang CC; Lo GH; Tai CM; Lin CW; Kao JH; Liu CJ; Liu CH; Yan SL; Bair MJ; Su WW; Chu CH; Chen CJ; Lo CC; Cheng PN; Chiu YC; Wang CC; Cheng JS; Tsai WL; Lin HC; Huang YH; Huang JF; Dai CY; Chuang WL; Yu ML; Peng CY
    J Gastroenterol Hepatol; 2021 Oct; 36(10):2884-2892. PubMed ID: 33963615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
    Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
    J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection: a propensity score analysis.
    Tada T; Kumada T; Toyoda H; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Yama T; Tanaka J
    Liver Int; 2016 Jun; 36(6):817-26. PubMed ID: 26787002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study.
    Colussi G; Donnini D; Brizzi RF; Maier S; Valenti L; Catena C; Cavarape A; Sechi LA; Soardo G
    World J Gastroenterol; 2019 Oct; 25(40):6094-6106. PubMed ID: 31686765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH).
    Yeh ML; Hung CH; Tseng KC; Lai HC; Chen CY; Kuo HT; Wang JH; Chen JJ; Lee PL; Chien RN; Yang CC; Lo GH; Tai CM; Lin CW; Kao JH; Liu CH; Yan SL; Bair MJ; Lin CY; Su WW; Chu CH; Chen CJ; Tung SY; Lo CC; Cheng PN; Chiu YC; Wang CC; Cheng JS; Tsai WL; Lin HC; Huang YH; Huang CF; Huang JF; Dai CY; Chuang WL; Tsai PC; Peng CY; Liu CJ; Yu ML
    Hepatol Int; 2021 Oct; 15(5):1109-1121. PubMed ID: 34365587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin.
    Ng KJ; Tseng CW; Chang TT; Tzeng SJ; Hsieh YH; Hung TH; Huang HT; Wu SF; Tseng KC
    Clin Interv Aging; 2016; 11():1035-41. PubMed ID: 27536084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimating the impact of early hepatitis C virus clearance on hepatocellular carcinoma risk.
    Darvishian M; Janjua NZ; Chong M; Cook D; Samji H; Butt ZA; Yu A; Alvarez M; Yoshida E; Ramji A; Wong J; Woods R; Tyndall M; Krajden M
    J Viral Hepat; 2018 Dec; 25(12):1481-1492. PubMed ID: 30047609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and predictors of cardiovascular disease, chronic kidney disease, and diabetes in HIV/HCV-coinfected patients who achieved sustained virological response.
    Leone S; Prosperi M; Costarelli S; Nasta P; Maggiolo F; Di Giambenedetto S; Saracino A; Di Pietro M; Gori A
    Eur J Clin Microbiol Infect Dis; 2016 Sep; 35(9):1511-20. PubMed ID: 27272121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C without sustained response to combination therapy.
    Chang KC; Ye YH; Wu CK; Lin MT; Tsai MC; Tseng PL; Hu TH
    J Formos Med Assoc; 2018 Nov; 117(11):1011-1018. PubMed ID: 29254684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in background characteristics of patients with chronic hepatitis C who achieved sustained virologic response with interferon-free versus interferon-based therapy and the risk of developing hepatocellular carcinoma after eradication of hepatitis C virus in Japan.
    Toyoda H; Tada T; Takaguchi K; Senoh T; Shimada N; Hiraoka A; Michitaka K; Ishikawa T; Kumada T
    J Viral Hepat; 2017 Jun; 24(6):472-476. PubMed ID: 27983762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained virological response from interferon-based hepatitis C regimens is associated with reduced risk of extrahepatic manifestations.
    Rossi C; Jeong D; Wong S; McKee G; Butt ZA; Buxton J; Wong J; Darvishian M; Bartlett S; Samji H; Yu A; Binka M; Alvarez M; Adu PA; Tyndall M; Krajden M; Janjua NZ;
    J Hepatol; 2019 Dec; 71(6):1116-1125. PubMed ID: 31433302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients.
    Hung CH; Lu SN; Wang JH; Hu TH; Chen CH; Huang CM; Lee CM
    Antivir Ther; 2011; 16(7):959-68. PubMed ID: 22024511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Late development of hepatocellular carcinoma after viral clearance in patients with chronic hepatitis C: A need for continual surveillance.
    Tong MJ; Theodoro CF; Salvo RT
    J Dig Dis; 2018 Jul; 19(7):411-420. PubMed ID: 29889353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early antiviral therapy reduces the risk of lymphoma in patients with chronic hepatitis C infection.
    Su TH; Liu CJ; Tseng TC; Chou SW; Liu CH; Yang HC; Wu SJ; Chen PJ; Chen DS; Chen CL; Kao JH
    Aliment Pharmacol Ther; 2019 Feb; 49(3):331-339. PubMed ID: 30592071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication.
    Huang CF; Yeh ML; Tsai PC; Hsieh MH; Yang HL; Hsieh MY; Yang JF; Lin ZY; Chen SC; Wang LY; Dai CY; Huang JF; Chuang WL; Yu ML
    J Hepatol; 2014 Jul; 61(1):67-74. PubMed ID: 24613362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis.
    Hsu WF; Chen CY; Tseng KC; Lai HC; Kuo HT; Hung CH; Tung SY; Wang JH; Chen JJ; Lee PL; Chien RN; Lin CY; Yang CC; Lo GH; Tai CM; Lin CW; Kao JH; Liu CJ; Liu CH; Yan SL; Bair MJ; Su WW; Chu CH; Chen CJ; Lo CC; Cheng PN; Chiu YC; Wang CC; Cheng JS; Tsai WL; Lin HC; Huang YH; Tsai PC; Huang JF; Dai CY; Chuang WL; Yu ML; Peng CY
    Sci Rep; 2020 Mar; 10(1):5372. PubMed ID: 32214132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection.
    Toyoda H; Kumada T; Tada T; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Ito T
    J Gastroenterol Hepatol; 2015 Jul; 30(7):1183-9. PubMed ID: 25678094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice?
    Christensen S; Buggisch P; Mauss S; Böker KHW; Schott E; Klinker H; Zimmermann T; Weber B; Reimer J; Serfert Y; Wedemeyer H
    Addiction; 2018 May; 113(5):868-882. PubMed ID: 29359361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.